- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03563053
Open-label, Long-term, Extension Treatment Using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients With Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study (OLE-IEDAT)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an international (North America, Europe, Africa, Asia and Australia), multi-center, prospective, open-label treatment study, designed to continue to provide the study medication to all patients who completed 12 months of treatment (including those treated with placebo) in the IEDAT-02-2015 trial, completed the study assessments, do not present safety contraindication to continuation of treatment, and provided informed consent. The study aims to collect information on the long-term safety and efficacy of the trial treatment. Patients meeting all selection criteria will receive monthly infusions of EDS-EP (dose range of ~14-22 mg DSP/infusion). If this dose of EDS-EP is not tolerated, the patient should be discontinued from the study. During the study, long-term efficacy assessments will be performed every 6 months, while safety parameters will be assessed at each monthly visit.
The ICARS, EQ-5D-5L and the CGI-C/S will be administered by a site rater. All patients enrolled in this study will have participated in Study IEDAT-02-2015, and there will be no de novo enrollment of new patients.
The Principal Investigator will ask all patients who meet the above requirements, and determine their interest in continuing to receive treatment with the study medication in a new protocol. The Principal Investigator will then determine the eligibility of the patients on the basis of his/her clinical judgement of patients' status and their safety.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Irene Maccabruni, BS
- Phone Number: +393458415028
- Email: irene.maccabruni@erydel.com
Study Locations
-
-
Victoria
-
Parkville, Victoria, Australia, 3052
- Completed
- Department of Neurology Royal Children's Hospital
-
-
-
-
-
Leuven, Belgium, 3000
- Completed
- Laboratory of Pediatric Immunology UZ Leuven
-
-
-
-
-
Frankfurt, Germany, 60590
- Completed
- Klinik für Kinder- und Jugendmedizin, Allergologie, pneumologie und Mukoviszidose, Universitätsklinikum Frankfurt
-
-
-
-
-
Bangalore, India, 560 029
- Completed
- National Institute of Mental Health and Neurosciences (NIMHANS) Department of Neurology
-
Chennai, India, 600 026
- Completed
- Vijaya Health Centre Department of Neurology
-
Hyderabad, India, 500 082
- Completed
- Nizam's Institute of Medical Sciences Department of Neurology
-
Mumbai, India, 400 026
- Completed
- Jaslok Hospital and Research Center Department of Pediatric Neurology
-
Mumbai, India, 400016
- Completed
- P.D. Hinduja National Hospital and Medical Research Centre Department of Pediatric Neurology
-
New Delhi, India, 110 029
- Completed
- All India Institute of Medical Sciences Child Neurology Division Department of Pediatrics
-
-
-
-
-
Roma, Italy
- Recruiting
- Dipartimento Neuroscienze umane e salute mentale, Policlinico Umberto I Università La Sapienza
-
Contact:
- Vincenzo Leuzzi, MD
- Email: vincenzo.leuzzi@uniroma1.it
-
-
-
-
-
Warsaw, Poland, 04-730
- Completed
- Department of Clinical Immunology - The Children's Memorial Health Institute
-
-
-
-
-
Madrid, Spain, 28046
- Completed
- Servicio de Neurolgia Pediatrica, Hospital Materno-Infantil La Paz
-
-
-
-
-
Tunis, Tunisia
- Recruiting
- Razi Hospital, Clinical Investigation Center-Neuroscience
-
Contact:
- Riadh Gouider, MD
- Email: riadh.gouider@gnet.tn
-
-
-
-
California
-
Los Angeles, California, United States, 90095
- Completed
- Ataxia Center and HD Center of Excellence - UCLA
-
-
Maryland
-
Baltimore, Maryland, United States, 21287-3923
- Completed
- Division of Pediatric Allergy and Immunology - Johns Hopkins Hospital
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Completed
- Cincinnati Children's Hospital Medical Center
-
-
Texas
-
Houston, Texas, United States, 77030
- Completed
- Department of Pediatrics Division of Child and Adolescent Neurology Mitochondrial Clinic - University of Texas Medical School
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient completed the double-blind period in the IEDAT-02-2015 trial and must have completed the final (Visit 15/Month 12) efficacy assessments of IEDAT-02-2015.
- Patient tolerated the study medication, without any evidence of steroid adverse events, or treatment-related severe/ serious adverse events
- Body weight > 15 kg.
- The patient and his/her parent/caregiver (if below the age of consent), or a legal representative, has provided written informed consent to participate. If consent is provided solely by the caregiver in accordance with local regulations, the patient must provide assent to participate in the study
- Patient does not present safety contraindication for continuation of treatment, as determined by the Principal Investigator (PI) according to the procedures described below.
Procedure for selecting patients for further treatment in IEDAT-03-2018:
The Principal Investigator will ask all patients who meet the above requirements, and determine their interest in continuing to receive treatment with the study medication in a new protocol. The Principal Investigator will then determine the eligibility of the patients on the basis of his/her clinical judgement of patients' status and their safety.
Exclusion Criteria:
General
Females that are
- pregnant, or are breast-feeding (for EU countries only);
- of childbearing potential, pregnant, or are breast-feeding (for US and Rest of World countries).
Females of childbearing potential using adequate birth control, as determined by their Health Care Provider, will be eligible.
- A disability that may prevent the patient from completing all study requirements.
Current participation in a clinical study with another investigational drug.
Medical History and Current Status
- CD4+ lymphocytes count <400/mm3 (for patients 6 years of age) or <200/mm3 (for patients >6 years).
- Current neoplastic disease.
- Severe impairment of the immunological system.
- Severe or unstable pulmonary disease.
- Uncontrolled diabetes. Patients with diabetes that has been stabilized (i.e. no hypoglycemic or hyperglycemic episodes in the past 3 months) will be eligible.
- Any other severe, unstable, or serious disease or condition that in the Investigator's opinion would put the patient at risk for imminent lifethreatening morbidity, need for hospitalization, or mortality.
- Eligibility of patients with abnormal laboratory test values will be determined by the Investigator.
- Confirmed hemoglobinopathies, e.g. hemoglobin C disease, sickle cell anemia, or thalassemia.
- Moderate or severe renal and/or hepatic impairment.
Patients who experienced moderate/ severe steroid side effects, or moderate/ severe adverse events associated with the study medication administered in the IEDAT-02 study.
Prior/Concomitant Medication
- Requires treatment with an oral or parenteral steroid. Treatment with inhaled or intranasal steroids for asthma or allergies, as well as use of topical steroids will be permitted.
- Requires any other concomitant medication prohibited by the protocol.
- Use of any drug that is a strong inducer/inhibitor of CYP3A4.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: active drug
~14-22 mg dexamethasone sodium phosphate (DSP)
|
EryDex System is a combination product that is used to load dexamethasone sodium phosphate (DSP) into autologous erythrocytes (EDS) creating the EDS-end product which is infused into the patients
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Long term safety/tolerability of EDS-EP: # of pts with treatment related Adverse Events (CTCAE4.0)
Time Frame: 1 year
|
AEs will be listed and summarized by body system and preferred term.
Incidence of AEs(%),intensity and relatedness to study drug will be reported.
SAEs and events newly occurring or worsening after administration of study medication will be summarized.
AEs that result in death/discontinuation of the study medication will be listed separately
|
1 year
|
Long term safety/tolerability of EDS-EP: lab parameters according to clinical practice such as hematology, biochemistry, urinalysis, HbA1c (haemoglobin A1c or glycated haemoglobin test), CD4+ lymphocytes count, CRP (C reactive protein)
Time Frame: 1 year
|
Values will be listed and summarized as normal or abnormal, according to local normal ranges, depending on the lab assessment (not possible to provide unique range and unit of measure due to changes from lab to lab).
Abnormal and clinically notable values will be identified and listed for each parameter
|
1 year
|
Long term safety/tolerability of EDS-EP: 12-lead ECG (Electrocardiography)
Time Frame: 1 year
|
Results will be listed and summarized as normal or abnormal, according guidelines (PR interval: < 100 msec or > 210 msec; QRS interval: < 50 msec or > 120 msec; QTc interval: > 450 msec; Heart rate: < 50 bpm (sinus bradycardia) or > 120 bpm (sinus tachycardia); Morphology: presence of T-wave inversion, abnormal R-waves, pathological Q-waves, significant ST elevation or depression).
Abnormal and clinically notable values will be identified and listed
|
1 year
|
Long term safety/tolerability of EDS-EP: physical and neurological exam
Time Frame: 1 year
|
Results will be listed and summarized as normal or abnormal, according to local assessment.
Examination includes general appearance,skin,neck(including thyroid),eyes/ears,nose,mouth,throat,lungs,heart, abdomen,back,lymphnodes,extremities,nervous system.
Abnormal and clinically notable values will be identified and listed for each parameter
|
1 year
|
Long term safety/tolerability of EDS-EP: Columbia Suicide Severity Rating Scale (CSSRS)
Time Frame: 1 year
|
Outcome will be listed and summarized on the basis of the answers: answer of "yes" to any of the 6 questions may indicate a need for referral to a trained mental health professional and an answer of "yes" to questions 4, 5 or 6 indicate high-risk
|
1 year
|
Long term safety/tolerability of EDS-EP: Bone Mineral Density
Time Frame: 1 year
|
Z-scores will be listed and summarized as normal or abnormal, following guidelines provided in the 2013 International Society for Clinical Densitometry Official Pediatric Position.
Abnormal and clinically notable values will be identified and listed for each parameter
|
1 year
|
Long term safety/tolerability of EDS-EP: Tanner staging
Time Frame: 1 year
|
The results (stages from I to V, according to the age, from 0 to 18) will be listed and summarized.
Abnormal and clinically notable values will be identified and listed for each parameter
|
1 year
|
Long term safety/tolerability of EDS-EP: sterility test
Time Frame: 1 year
|
Outcome can be Positive or negative.
Results will be listed and summarized
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the long-term effect of EDS-EP on health related Quality of Life (EQ-5D-5L scale: EuroQol 5 dimension 5 level scale)
Time Frame: 1 year
|
Descriptive analyses will be performed to evaluate the long-term effects of EDS-EP on health-related Quality of Life (QoL), assessed by EQ-5D-5L scale.
EQ-5D-5L descriptive system scoring: from 5, min/worst, to 25, best/max); EQ-VAS (EQ Visual Analogue scale) scoring: from 0, min/worst, to 100, best/max
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Guenter R Janhofer, MD, EryDel S.p.A.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Neurologic Manifestations
- Genetic Diseases, Inborn
- Dyskinesias
- DNA Repair-Deficiency Disorders
- Neurocutaneous Syndromes
- Cerebellar Diseases
- Primary Immunodeficiency Diseases
- Spinocerebellar Ataxias
- Ataxia
- Telangiectasis
- Cerebellar Ataxia
- Ataxia Telangiectasia
Other Study ID Numbers
- IEDAT-03-2018
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ataxia Telangiectasia
-
Matrix Biomed, Inc.The University of Texas Health Science Center, HoustonNot yet recruitingAtaxia Telangiectasia | Ataxia Telangiectasia Louis-Bar | Ataxia Telangiectasia in ChildrenUnited States
-
Johns Hopkins UniversityTerminatedAtaxia-Telangiectasia (A-T)United States
-
NHS TaysideUniversity of DundeeCompletedAtaxia-TelangiectasiaUnited Kingdom
-
St. Jude Children's Research HospitalNational Cancer Institute (NCI); Children's Hospital of PhiladelphiaCompletedAtaxia-TelangiectasiaUnited States
-
Institute of Child HealthGreat Ormond Street Hospital for Children NHS Foundation TrustCompletedAtaxia Telangiectasia (AT)United Kingdom
-
University of PlymouthRecruitingAtaxia Telangiectasia | Ataxia Telangiectasia in ChildrenUnited Kingdom
-
The University of QueenslandNational Health and Medical Research Council, AustraliaCompletedAtaxia TelangiectasiaAustralia
-
ErydelBiotrialNot yet recruitingAtaxia TelangiectasiaBelgium, United States, Denmark, Germany, Italy, Norway, Poland, Spain, United Kingdom
-
Acasti Pharma Inc.Active, not recruitingAtaxia TelangiectasiaCanada
-
University Hospital, AkershusOslo University Hospital; University Hospital of North Norway; University of... and other collaboratorsActive, not recruitingAtaxia TelangiectasiaNorway
Clinical Trials on EryDex System
-
ErydelCompletedGenetic Syndrome | Nervous System DiseaseIndia, United States, Israel, Australia, Belgium, Germany, Italy, Norway, Poland, Spain, Tunisia, United Kingdom
-
ResMedCompleted
-
Federal University of São PauloCompletedAdverse Reaction to Systemic AgentsBrazil
-
KineticureCompletedOsteoarthritis | Knee PainUnited States
-
Smith & Nephew, Inc.CompletedDiabetic Foot Ulcers | Venous Leg UlcersUnited States, Canada
-
Molnlycke Health Care ABCompletedEvaluation of Negative Pressure Wound Therapy in the Treatment of DFUs Incl. Post Amputation Wounds.Diabetes | Foot UlcersUnited Kingdom
-
Zahedan University of Medical SciencesUnknownPain, Postoperative Pain Pathologic Processes Postoperative Complications Signs and Symptoms